Related Experiment Video
Updated: Jan 3, 2026

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells
Published on: March 5, 2019
Pro-inflammatory Cytokines and Resistant Hypertension: Potential for Novel Treatments?
Mariana Rodrigues Pioli1, Ana Paula de Faria2
1Department of Pharmacology, FCM 10 Building, School of Medical Sciences - University of Campinas (FCM-UNICAMP), Tessália Vieira de Camargo, 126, Campinas, SP, 13083-970, Brazil.
Purpose Of Review:
To gather data from studies evaluating the pro-inflammatory profile of individuals with resistant hypertension (RH), and bring a clinical update of new and potential complementary therapies to treat inflammation in RH.
Recent Findings:
Increases in pro-inflammatory cytokines are related to elevated blood pressure and target organ damage in RH patients. Clinical and experimental studies have shown that some biological therapies, especially TNF-α inhibitors, regulated pro- and anti-inflammatory cytokines associated with improvements in clinical outcomes, although they are not yet reported in RH. New emerging therapies to treat inflammation in RH, although promising, are still hypotheses that have not been scientifically confirmed in clinical trials. For this reason, inflammation-target treatments, such as the TNF-α and IL-6 inhibitors, should be encouraged for testing as complementary therapies in RH in order to elucidate their potential benefits.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension II: Pathophysiology
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Hypertension and Regulation of Blood Pressure

